• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

Zonisamide

Product ID Z5653
Cas No. 68291-97-4
Purity ≥96%
Product Unit SizeCostQuantityStock
10 mg $92.50 In stock
25 mg $203.70 In stock
100 mg $685.20 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Zonisamide is a sulfonamide that exhibits antiepileptic/anticonvulsant and neuroprotective activity and is clinically used to prevent seizures and epilepsy. Zonisamide inhibits carbonic anhydrase, voltage-gated Na+ channels, and T-type Ca2+ channels, and modulates release of GABA and glutamate. In animal models of Parkinson’s disease, zonisamide delays neurodegeneration.

Product Info

Cas No.

68291-97-4

Purity

≥96%

Formula

C8H8N2O3S

Formula Wt.

212.23

Chemical Name

1,2-Benzisoxazole-3-methanesulfonamide

IUPAC Name

1,2-benzoxazol-3-ylmethanesulfonamide

Synonym

AD-810, CI-912, Excegran, Zonegran

Melting Point

160-163°C

Solubility

Sparingly soluble in water. Soluble in methanol, ethanol, DMSO.

Appearance

White crystalline powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

Z5653 MSDS PDF

Info Sheet

Z5653 Info Sheet PDF

Brochures

Zonisamide Flyer

References

Arawaka S, Fukushima S, Sato H, et al. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease. PLoS One. 2014 Feb 20;9(2):e89076. PMID: 24586512.

Aggarwal M, Kondeti B, McKenna R. Anticonvulsant/antiepileptic carbonic anhydrase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(6):717-24. PMID: 23514045.

Holder JL Jr, Wilfong AA. Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2011 Nov;12(16):2573-81. PMID: 21967409.

Baulac M, Leppik IE. Efficacy and safety of adjunctive zonisamide therapy for refractory partial seizures. Epilepsy Res. 2007 Jul;75(2-3):75-83. PMID: 17553670.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only